EUCTR2004-002673-22-IT进行中（未招募）不适用
Double-blind, placebo controlled, randomized, multicenter, parallel-group study to compare the efficacy and safety of Advantan cream twice weekly with Advabase cream during a maintenance phase of 16 weeks after successful treatment of Atopic Dermatitis with Advantan cream
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- SCHERING
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Double-blind, placebo controlled, randomized, multicenter, parallel-group study to compare the efficacy and safety of Advantan cream twice weekly with Advabas cream during a maintenance phase of 16 weeks after successful treatment of Atopic Dermatitis with Advantan cream - Advantan maintenance studyMedDRA version: 7.1Level: PTClassification code 10012438Atopic DermatitisEUCTR2004-002673-22-DESchering AG250
进行中（未招募）
1 期
Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSOPatients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment.MedDRA version: 9.1Level: LLTClassification code 10034006Term: Parkinson's disease aggravatedEUCTR2005-001006-12-CZAxxonis Pharma GmbH60
进行中（未招募）
1 期
Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSOPatients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment.MedDRA version: 9.1Level: LLTClassification code 10034006Term: Parkinson's disease aggravatedEUCTR2005-001006-12-DEAxxonis Pharma GmbH60
进行中（未招募）
不适用
Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safety of Lisparin®, applied subcutaneously by means of a minipump in patients with advanced Parkinson’s Disease refractory to conventional oral therapy. - CALIPSOPatients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to conventional treatment.EUCTR2005-001006-12-ATAxxonis Pharma GmbH60
已完成
3 期
To prove the therapeutic efficacy and tolerability of Ichthraletten® versus placebo in case of mild to moderate Acne papulopustulosa.CTRI/2009/091/000791ICHTHYOLCompany Cordes Hermanni and Co120